WO2023147169A3 - Novel liquid formulations for iron chelation - Google Patents

Novel liquid formulations for iron chelation Download PDF

Info

Publication number
WO2023147169A3
WO2023147169A3 PCT/US2023/011981 US2023011981W WO2023147169A3 WO 2023147169 A3 WO2023147169 A3 WO 2023147169A3 US 2023011981 W US2023011981 W US 2023011981W WO 2023147169 A3 WO2023147169 A3 WO 2023147169A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
ferroptosis
liquid formulations
novel liquid
iron chelation
Prior art date
Application number
PCT/US2023/011981
Other languages
French (fr)
Other versions
WO2023147169A2 (en
Inventor
Rajiv Bhushan
Amit Goswamy
Original Assignee
LIVIONEX, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LIVIONEX, Inc. filed Critical LIVIONEX, Inc.
Publication of WO2023147169A2 publication Critical patent/WO2023147169A2/en
Publication of WO2023147169A3 publication Critical patent/WO2023147169A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Iron-chelating formulations, comprising a chelator (such as EDTA and its salts) and methylsulfonylmethane (MSM), are provided. The formulation can be a ready-to-drink beverage, a hydration drip, or any liquid that can be systemically administered to a subject. Formulations and methods for treatment of RNA viruses including SARS-CoV-2 using the disclosed composition is provided. Formulations and methods for inhibition of ferroptosis and diseases and conditions affected by ferroptosis is provided. Among diseases and conditions affected by ferroptosis are cancer, aging, inflammation, and the like.
PCT/US2023/011981 2022-01-31 2023-01-31 Novel liquid formulations for iron chelation WO2023147169A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263305099P 2022-01-31 2022-01-31
US63/305,099 2022-01-31

Publications (2)

Publication Number Publication Date
WO2023147169A2 WO2023147169A2 (en) 2023-08-03
WO2023147169A3 true WO2023147169A3 (en) 2023-09-28

Family

ID=87472463

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/011981 WO2023147169A2 (en) 2022-01-31 2023-01-31 Novel liquid formulations for iron chelation

Country Status (1)

Country Link
WO (1) WO2023147169A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031761A1 (en) * 2003-08-05 2005-02-10 Donald Brucker Methods of producing a functionalized coffee
US20100035992A1 (en) * 2008-03-11 2010-02-11 Rajiv Bhushan Methods and Compositions for Treating Inflammation and Inflammation-Related Pathologies
US20120225053A1 (en) * 2005-05-24 2012-09-06 Slavik Dushenkov Compositions and methods for the prevention and treatment of conditions associated with inflamation
US20150335557A1 (en) * 2012-12-20 2015-11-26 Rajiv BHUSNAN Anti-plaque oral compositions
US20170056347A1 (en) * 2015-09-01 2017-03-02 First Wave Biopharma Methods and compositions for treating conditions associated with an abnormal inflammatory responses
US20170215417A1 (en) * 2012-12-20 2017-08-03 LIVIONEX, Inc. Antimicrobial compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031761A1 (en) * 2003-08-05 2005-02-10 Donald Brucker Methods of producing a functionalized coffee
US20120225053A1 (en) * 2005-05-24 2012-09-06 Slavik Dushenkov Compositions and methods for the prevention and treatment of conditions associated with inflamation
US20100035992A1 (en) * 2008-03-11 2010-02-11 Rajiv Bhushan Methods and Compositions for Treating Inflammation and Inflammation-Related Pathologies
US20150335557A1 (en) * 2012-12-20 2015-11-26 Rajiv BHUSNAN Anti-plaque oral compositions
US20170215417A1 (en) * 2012-12-20 2017-08-03 LIVIONEX, Inc. Antimicrobial compositions
US20170056347A1 (en) * 2015-09-01 2017-03-02 First Wave Biopharma Methods and compositions for treating conditions associated with an abnormal inflammatory responses

Also Published As

Publication number Publication date
WO2023147169A2 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
MX2021006026A (en) Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof.
CR20220363A (en) Substituted tricyclic compounds
CR20210563A (en) Compounds and methods for the treatment of covid-19
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
MX2021010106A (en) Inhibitors of integrated stress response pathway.
EA201500769A1 (en) E1 INHIBITORS ACTIVATING ENZYMES
EP2513343A4 (en) Methods and compositions for treating inflammation of skin
RU2015115064A (en) COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS
WO2019199861A3 (en) Hemp extract for treatment of pain in animals
MX2020005621A (en) Fatty acid derivatives for treating non-alcoholic steatohepatitis.
MX2011009709A (en) Compounds for treating inflammation and pain.
MX2022015531A (en) Pyridine-pyrimidine derivative, preparation method therefor and pharmaceutical use thereof.
AU2018246796A1 (en) S1PR4-targeting composition for preventing or treating non-alcoholic steatohepatitis
WO2013142038A3 (en) Compositions and methods for inhibition of cathepsins
MX2021005240A (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents.
WO2009015485A8 (en) Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
MX2021001276A (en) Bismuth-thiol compositions and methods for treating wounds.
MX2015017879A (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase.
MX2023003846A (en) Biphenyl compound as immunomodulator, preparation method therefor and application thereof.
MX2021009535A (en) Use of topical braf inhibitor compositions for treatment of radiation dermatitis.
WO2023147169A3 (en) Novel liquid formulations for iron chelation
WO2020132560A3 (en) Compositions and methods for cancer therapy
WO2013168013A3 (en) Compositions and methods for the treatment of chronic diseases and inflammatory disorders
WO2023205481A9 (en) Bavdegalutamide and combinations thereof for use in treating prostate cancer
MX2022011565A (en) Boronic acid derivatives and therapeutic uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23747718

Country of ref document: EP

Kind code of ref document: A2